Why decarbonisation is now central to Ireland’s MedTech competitiveness
A new Irish Medtech and Ibec report shows that sustainability is becoming a strategic requirement for Ireland’s €20 billion MedTech sector, shaping manufacturing, supply chains, product design and future competitiveness.
Ireland’s MedTech sector has become one of the country’s strongest industrial success stories. It is a global hub for medical technology manufacturing, employing more than 50,000 people across more than 500 companies and delivering over €20 billion in annual exports.
That position brings opportunity, but also responsibility.
A new Irish Medtech and Ibec report, Irish Medtech Pathways to Net Zero 2026, sets out why decarbonisation is becoming essential to protect Ireland’s MedTech competitiveness. The report makes clear that sustainability is no longer a separate environmental issue. It is now directly linked to business resilience, supply-chain strength, customer expectations, regulatory readiness and long-term industrial growth.
For a sector built around patient safety, regulatory compliance and global supply chains, the transition to net zero is not simple. Medical device manufacturers operate in highly controlled environments. Products often require strict validation, carefully approved materials, sterile production, precision engineering and long product lifecycles. This means decarbonisation cannot be approached in the same way as in less regulated sectors.
However, the direction of travel is clear.
The report shows that Irish MedTech companies are already taking action. Sustainability is now firmly embedded as a strategic concern, with 92% of surveyed organisations identifying it as either a top strategic priority or a recognised business priority. This is an important signal. It shows that companies are not treating sustainability as a branding exercise, but as part of how they remain competitive in a changing global market.
This matters because the pressures on MedTech manufacturers are increasing from several directions at once. Regulation is evolving. Customers are asking more questions about environmental performance. Investors are looking for credible transition plans. Procurement teams are beginning to assess lifecycle impact. At the same time, energy costs, supply-chain disruption, materials availability and infrastructure constraints are creating direct operational risks.
One of the strongest messages from the report is that decarbonisation in MedTech is a value-chain challenge. While many companies are already monitoring Scope 1 and Scope 2 emissions, only 28% of surveyed organisations are currently monitoring Scope 1, Scope 2 and Scope 3 emissions comprehensively. This matters because the majority of MedTech emissions sit beyond the factory gate, across raw materials, product use, end-of-life, packaging and global supply chains.
That creates a difficult but important challenge for manufacturers. A company may have strong control over its own facility, but far less influence over upstream suppliers, materials, logistics and end-of-life routes. The report highlights that supplier engagement remains at an early stage for much of the sector, with only 12% of companies reporting a comprehensive, structured supplier sustainability programme.
For SMEs, this challenge can be particularly difficult. Smaller companies may face the same customer and regulatory expectations as larger companies, but with fewer internal resources, less buying power and less leverage over global suppliers. The report notes that limited internal resources and lack of supplier influence are among the most significant barriers to supplier sustainability engagement.
This is where collaboration becomes critical. No single company can solve Scope 3 emissions alone. Better data, standardised supplier requests, shared expectations, common templates, industry platforms and targeted support will all be needed if the sector is to move from ambition to measurable progress.
The report also highlights the importance of sustainable product design. More than half of surveyed companies are already integrating sustainable design principles either across selected products or across all product lines. Common approaches include lower-impact or alternative materials, improved resource and energy efficiency, lifecycle assessments and circular design principles.
However, the barriers are significant. The most widely reported challenge is the lack of suitable alternative materials, cited by 76% of companies. This is not surprising. In MedTech, material choices are rarely simple. Materials must meet strict requirements around performance, sterility, biocompatibility, durability and regulatory approval. Substituting one material for another can trigger validation, regulatory review, supply-chain changes and product lifecycle risk.
That is why sustainable MedTech manufacturing is not only about reducing emissions from buildings or energy systems. It is also about future materials, product redesign, process innovation, packaging, sterilisation, logistics and regulatory alignment. These are advanced manufacturing challenges as much as sustainability challenges.
Energy is another major theme. The report shows that electricity is used by 96% of respondents, while 60% rely on natural gas and 48% use oil-based fuels such as diesel or gasoline. Only 24% reported using renewable energy sources. This reflects the reality that many MedTech facilities require energy-intensive processes, including cleanrooms, temperature-controlled production, sterilisation and high-precision manufacturing.
The move away from fossil-fuel-based heat is underway, but uneven. Some companies are transitioning operations or running pilot projects, while others have no current plans. For many manufacturers, the barriers are not simply willingness or ambition. Grid capacity, process heat requirements, technology readiness, capital cost, infrastructure constraints and energy reliability all affect the pace of change.
This is an important point for policy and industry. If Ireland wants to protect and grow its MedTech manufacturing base, decarbonisation must be supported by the right infrastructure. Companies can invest in efficiency, renewable energy, process optimisation and cleaner technologies, but they need reliable energy systems, predictable costs and practical support for capital investment.
The report identifies a set of practical actions companies can take now. These include improving energy efficiency, switching to renewable electricity where possible, using data to identify process improvements, engaging priority suppliers, reducing scrap and rework, improving logistics and integrating climate and energy risks into business continuity planning.
These are “no-regrets” actions. They can reduce emissions, lower cost, improve resilience and strengthen competitiveness, without requiring companies to immediately solve every complex challenge in the value chain.
For Ireland’s MedTech sector, the message is clear. Decarbonisation is not separate from innovation. It is becoming part of how products are designed, how manufacturing processes are improved, how suppliers are managed and how companies remain competitive in international markets.
This is especially relevant for SMEs working across Health and Life Sciences manufacturing. As larger companies, customers and regulators increase expectations, SMEs will need support to understand where to start, what data to collect, how to identify practical improvement opportunities and how to connect sustainability with product and process innovation.
The Irish Medtech and Ibec report shows a sector that is moving in the right direction, but also one that faces real barriers. The opportunity now is to turn strategic intent into practical action: better data, smarter design, stronger supplier collaboration, more efficient manufacturing and clearer pathways to lower-carbon production.
Ireland’s MedTech sector has already built a strong global position. The next challenge is to ensure that position remains resilient, competitive and sustainable in a low-carbon future.
Original article